Anders Hinsby

Chief Executive Officer & Director at Dansk Biotek

Anders Hinsby

Anders Hinsby

Chief Executive Officer & Director at Dansk Biotek

Overview
Career Highlights

Dansk Biotek
Orphazyme A/S

RelSci Relationships

182

Number of Boards

3

Birthday

1973

Age

48

Contact Data
Trying to get in touch with Anders Hinsby? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Anders Hinsby likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Inthera Bioscience AG

Relationship likelihood: Strong

Founding Member at Bankinvest Biomedical Venture

Relationship likelihood: Strong

Chief Financial Officer at Orphazyme A/S

Relationship likelihood: Strong

Professional at Novozymes Biotech, Inc.

Relationship likelihood: Strong

General Partner & Founder at Sunstone Capital A/S

Relationship likelihood: Strong

Co-Founder & Managing Director at Vico Therapeutics

Relationship likelihood: Strong

Entrepreneur Partner at Polaris Partners

Relationship likelihood: Strong

Chief Executive Officer at Asarina Pharma AB

Relationship likelihood: Strong

Managing Partner Seed Investments at Novo Holdings A/S

Relationship likelihood: Strong

Founder at LSP Management Group BV

Relationship likelihood: Strong

Paths to Anders Hinsby
Potential Connections via
Relationship Science
You
Anders Hinsby
Chief Executive Officer & Director at Dansk Biotek
Education
Ph.D in Medicine
Career History
Assistant Professor in Systems Biology
Prior

For almost two centuries DTU, Technical University of Denmark, has been dedicated to fulfilling the vision of H.C. rsted the father of electromagnetism who founded the university in 1829 to develop and create value using the natural sciences and the technical sciences to benefit society. Today, DTU is ranked as one of the foremost technical universities in Europe, continues to set new records in the number of publications, and persistently increase and develop our partnerships with industry, and assignments accomplished by DTU's public sector consultancy.

Partner
2009 - 2010

BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio.The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties.BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services.BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years.Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam.

Professional
Prior

Novo Ventures is an active manager which provides funding for early and later-stage capital requirements, and provides management support. The firm invests in both public and private companies from Northern Europe and the United States. Novo Ventures targets companies operating in the health technology and health services sector, and industries such as biotechnology and medical specialties. It looks to take minority stake positions in its investments, as well as a seat on the board.

Boards & Committees
Independent Director
2020 - Current
Chief Executive Officer & Director
Current
Non-Executive Director
Prior
Investments
Details Hidden

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anders Hinsby. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anders Hinsby's profile does not indicate a business or promotional relationship of any kind between RelSci and Anders Hinsby.